IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.
Zacks Investment Research9/16/2026Positive
IQV
IQVIA Holdings IncNYSEHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$45.27B
P/E Ratio
34.25
EPS
$8.03
Beta
1.19
52W High
$277.40
52W Low
$154.50
50-Day MA
$246.40
200-Day MA
$204.52
Dividend Yield
—
Profit Margin
8.10%
Forward P/E
18.42
PEG Ratio
0.97
About IQVIA Holdings Inc
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Fundamentals
| Revenue (TTM) | $16.98B |
| Gross Profit (TTM) | $5.60B |
| EBITDA | $3.05B |
| Operating Margin | 13.00% |
| Return on Equity | 22.80% |
| Return on Assets | 5.06% |
| Revenue/Share (TTM) | $100.70 |
| Book Value | $37.49 |
| Price-to-Book | 7.14 |
| Price-to-Sales (TTM) | 2.67 |
| EV/Revenue | 3.43 |
| EV/EBITDA | 16.51 |
| Quarterly Earnings Growth (YoY) | -0.60% |
| Quarterly Revenue Growth (YoY) | 8.70% |
| Shares Outstanding | $164.60M |
| Float | $156.25M |
| % Insiders | 1.09% |
| % Institutions | 103.43% |
Historical Volatility
HV 10-Day
21.83%
HV 20-Day
25.26%
HV 30-Day
25.84%
HV 60-Day
38.23%
HV Rank
24.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($277.94 target)
3
Strong Buy15
Buy3
HoldLatest News
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research9/11/2026Positive
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical.
Business Wire9/3/2026Neutral
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial executio.
Business Wire8/27/2026Neutral
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research8/27/2026Positive
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
Zacks Investment Research8/26/2026Positive
IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. Powered by IQVIA Healthcare-grade AI®, the tool tackles a long-standing proble.
Business Wire8/20/2026Neutral
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group's “Top 50™ Pharmaceutical Technology Providers” report for 2026. IQVIA earned the highest overall score among the 50 providers evaluated, receiving 96.8 out of 100. The ranking recognizes IQVIA's broad technology cover.
Business Wire8/17/2026Neutral
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.
Zacks Investment Research8/12/2026Positive
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research8/10/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IQV and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026